debt_leverage_profile
1.98x Total Debt / Equity (Elevated leverage)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; CV Sciences carries minimal long-term debt (~$2M), so a 200bps rate rise increases annual interest expense by ~$40K, immaterial to operations.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Chinese hemp/CBD extract sourcing disruption; 2) Colorado/Kentucky domestic hemp harvest concentration risk from weather or regulatory shifts.
Inferred
Agent_Inference
international_expansion_readiness
CV Sciences derives ~95%+ revenue domestically; international revenue is negligible, so sovereign currency devaluation exposure is effectively zero.
Inferred
Agent_Inference
geographic_footprint
Predominantly US-only revenue base; no material international markets, rendering sovereign currency devaluation risk essentially null.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single hemp extract supplier concentration is high; proprietary hemp genetics (CVSI-007) sourced from limited contract growers likely exceeds 30% of COGS input dependency.
Inferred
Agent_Inference
business_model_type_primary
Physical consumer packaged goods; cloud infrastructure termination would disrupt e-commerce/DTC channel (~30-40% of sales) but not manufacturing or retail distribution.
Inferred
Agent_Inference
business_model_type_secondary
B2B specialty pharmaceutical pipeline (CVSI-007); cloud termination has minimal impact on drug development operations, which are lab- and CRO-dependent.
Inferred
Agent_Inference
switching_cost_profile
Minimal API coupling risk; company operates standard e-commerce (Shopify/similar) and ERP stacks with readily substitutable platforms.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is product sales (hemp CBD supplements), not investment contracts. No expectation of profit from others' efforts.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate CCPA exposure via DTC e-commerce customer data; GDPR risk near-zero given negligible EU operations. Basic compliance infrastructure likely adequate.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; CV Sciences holds less than 5% of fragmented US CBD market with hundreds of competitors and no dominant market position.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~85-90% transactional (retail/DTC product sales); minimal recurring revenue. Subscription wellness programs exist but represent <10% of total revenue.
Inferred
Agent_Inference
monetization_vector
Per-unit product sales of hemp CBD supplements through retail (Whole Foods, CVS, Vitamin Shoppe) and direct-to-consumer e-commerce channels.
Inferred
Agent_Inference
pricing_architecture
Value-brand CBD pricing (~$20-$60/product); vulnerable to commodity hemp price deflation and private-label competition compressing margins below breakeven.
Inferred
Agent_Inference
pricing_power_rating
Weak; 2/5 rating. CBD market commoditization, low brand differentiation, and regulatory uncertainty limit ability to sustain price increases above inflation.
Inferred
Agent_Inference
target_gross_margin_bracket
49.0% Gross Margin (Strong (40-60%))
High
SEC-XBRL
churn_vulnerability_index
Moderate free-rider risk; consumers can easily switch to private-label or competing CBD brands with similar efficacy claims and lower price points.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is sublinear to headcount; manufacturing is largely outsourced. Doubling revenue requires ~20-30% headcount increase, primarily in sales/marketing.
Inferred
Agent_Inference
marginal_cost_of_growth
Moderate; primary marginal costs are COGS (hemp extract, manufacturing) and marketing spend. Gross margins ~50%, but SG&A intensity remains high (~60% of revenue).
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC would likely compress via retail leverage, but customer LTV remains low (~$120-150 estimated) given high category churn and commodity competition.
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; CBD supplement purchasing is individual, non-social, and product utility does not increase with more users.
Inferred
Agent_Inference
asset_efficiency_ratio
-13.6% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 3 (recession-vulnerable); CBD supplements are discretionary wellness purchases. Consumer trading-down to private label or elimination likely during downturns.
Inferred
Agent_Inference
customer_segment_primary
Health-conscious adult consumers (35-65, female-skewing) purchasing hemp CBD supplements for wellness, anxiety, and sleep support through retail and DTC channels.
Inferred
Agent_Inference
customer_segment_secondary
Retail pharmacy and natural grocery channel buyers (CVS, Vitamin Shoppe, Whole Foods) as B2B customers; no single retailer likely exceeds 20% of revenue.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.8% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001510964
High
SEC-EDGAR
ticker
CVSI
High
SEC-EDGAR